Antithrombin and hypercoagulability in sepsis: insights from thrombelastography?

Area of Science:

• Hematology
• Critical Care Medicine
• Pharmacology

Background:

• Antithrombin (AT) is a long-established treatment for disseminated intravascular coagulation (DIC), with proven survival benefits in specific patient cohorts.
• The KyberSept trial indicated a survival advantage for AT therapy in DIC patients not concurrently treated with heparin.
• Severe sepsis is associated with hypercoagulability, characterized by altered thrombelastography (TEG) parameters compared to healthy individuals.

Discussion:

• Gonano and colleagues observed hypercoagulability in severe sepsis patients using five TEG parameters.
• A trend towards normalization of TEG parameters was noted in the AT treatment group, but this did not achieve statistical significance.
• This study represents the initial clinical assessment of hypercoagulability during AT therapy for sepsis.

Key Insights:

• The study did not provide conclusive evidence that AT therapy attenuates coagulopathy in severe sepsis.
• High inter-individual variability in patient responses may obscure the potential effects of AT on coagulopathy.
• Thrombelastography (TEG) can detect hypercoagulability in severe sepsis, but its normalization with AT treatment requires further investigation.

Outlook:

• Further research is needed to elucidate the precise mechanisms and clinical efficacy of AT in modulating hypercoagulability during sepsis.
• Investigating patient stratification based on variability could optimize the use of AT therapy in critical care settings.
• Future studies should aim for larger sample sizes and standardized protocols to confirm or refute the observed trends.